Search

Your search keyword '"Travis, Simon P."' showing total 652 results
Start Over Author "Travis, Simon P."
652 results on '"Travis, Simon P."'

1. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.

Author

Thomas, Tom, Friedrich, Matthias, Rich-Griffin, Charlotte, Pohin, Mathilde, Agarwal, Devika, Pakpoor, Julia, Lee, Carl, Tandon, Ruchi, Rendek, Aniko, Aschenbrenner, Dominik, Jainarayanan, Ashwin, Voda, Alexandru, Siu, Jacqueline, Sanches-Peres, Raphael, Nee, Eloise, Sathananthan, Dharshan, Kotliar, Dylan, Todd, Peter, Kiourlappou, Maria, Gartner, Lisa, Ilott, Nicholas, Issa, Fadi, Hester, Joanna, Turner, Jason, Nayar, Saba, Mackerodt, Jonas, Zhang, Fan, Jonsson, Anna, Brenner, Michael, Raychaudhuri, Soumya, Kulicke, Ruth, Ramsdell, Danielle, Stransky, Nicolas, Pagliarini, Ray, Bielecki, Piotr, Spies, Noah, Marsden, Brian, Taylor, Stephen, Wagner, Allon, Klenerman, Paul, Walsh, Alissa, Coles, Mark, Jostins-Dean, Luke, Powrie, Fiona, Filer, Andrew, Travis, Simon, Uhlig, Holm, Dendrou, Calliope, and Buckley, Christopher

Subjects
Humans, Single-Cell Analysis, Adalimumab, Inflammatory Bowel Diseases, Crohn Disease, Longitudinal Studies, Colitis, Ulcerative, Tumor Necrosis Factor-alpha, Transcriptome, Female, Adult, Male, Interferons, Signal Transduction, Arthritis, Rheumatoid
Abstract

Precision medicine in immune-mediated inflammatory diseases (IMIDs) requires a cellular understanding of treatment response. We describe a therapeutic atlas for Crohns disease (CD) and ulcerative colitis (UC) following adalimumab, an anti-tumour necrosis factor (anti-TNF) treatment. We generated ~1 million single-cell transcriptomes, organised into 109 cell states, from 216 gut biopsies (41 subjects), revealing disease-specific differences. A systems biology-spatial analysis identified granuloma signatures in CD and interferon (IFN)-response signatures localising to T cell aggregates and epithelial damage in CD and UC. Pretreatment differences in epithelial and myeloid compartments were associated with remission outcomes in both diseases. Longitudinal comparisons demonstrated disease progression in nonremission: myeloid and T cell perturbations in CD and increased multi-cellular IFN signalling in UC. IFN signalling was also observed in rheumatoid arthritis (RA) synovium with a lymphoid pathotype. Our therapeutic atlas represents the largest cellular census of perturbation with the most common biologic treatment, anti-TNF, across multiple inflammatory diseases.

Published
2024

5. Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards

Author

Uhlig, Holm H., Booth, Claire, Cho, Judy, Dubinsky, Marla, Griffiths, Anne M., Grimbacher, Bodo, Hambleton, Sophie, Huang, Ying, Jones, Kelsey, Kammermeier, Jochen, Kanegane, Hirokazu, Koletzko, Sibylle, Kotlarz, Daniel, Klein, Christoph, Lenardo, Michael J., Lo, Bernice, McGovern, Dermot P. B., Özen, Ahmet, de Ridder, Lissy, Ruemmele, Frank, Shouval, Dror S., Snapper, Scott B., Travis, Simon P., Turner, Dan, Wilson, David C., and Muise, Aleixo M.

Published
2023
Full Text
View/download PDF

7. Biallelic TLR4 deficiency in humans

Author

Capitani, Melania, Al-Shaibi, Ahmad A., Pandey, Sumeet, Gartner, Lisa, Taylor, Henry, Hubrack, Satanay Z., Agrebi, Nourhen, Al-Mohannadi, Muneera Jassim, Al Kaabi, Saad, Vogl, Thomas, Roth, Johannes, Kotlarz, Daniel, Klein, Christoph, Charles, Adrian K., Vijayakumar, Vinayan, Karim, Mohammed Yousuf, George, Bruce, Travis, Simon P., Elawad, Mamoun, Lo, Bernice, and Uhlig, Holm H.

Published
2023
Full Text
View/download PDF

9. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

Author

Ma, Christopher, Hanzel, Jurij, Panaccione, Remo, Sandborn, William J., D’Haens, Geert R., Ahuja, Vineet, Atreya, Raja, Bernstein, Charles N., Bossuyt, Peter, Bressler, Brian, Bryant, Robert V., Cohen, Benjamin, Colombel, Jean-Frederic, Danese, Silvio, Dignass, Axel, Dubinsky, Marla C., Fleshner, Phillip R., Gearry, Richard B., Hanauer, Stephen B., Hart, Ailsa, Kotze, Paulo Gustavo, Kucharzik, Torsten, Lakatos, Peter L., Leong, Rupert W., Magro, Fernando, Panés, Julian, Peyrin-Biroulet, Laurent, Ran, Zhihua, Regueiro, Miguel, Singh, Siddharth, Spinelli, Antonino, Steinhart, A. Hillary, Travis, Simon P., van der Woude, C. Janneke, Yacyshyn, Bruce, Yamamoto, Takayuki, Allez, Matthieu, Bemelman, Willem A., Lightner, Amy L., Louis, Edouard, Rubin, David T., Scherl, Ellen J., Siegel, Corey A., Silverberg, Mark S., Vermeire, Severine, Parker, Claire E., McFarlane, Stefanie C., Guizzetti, Leonardo, Smith, Michelle I., Vande Casteele, Niels, Feagan, Brian G., and Jairath, Vipul

Published
2022
Full Text
View/download PDF

12. Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Author

Tomic, Adriana, Skelly, Donal T., Ogbe, Ane, O’Connor, Daniel, Pace, Matthew, Adland, Emily, Alexander, Frances, Ali, Mohammad, Allott, Kirk, Azim Ansari, M., Belij-Rammerstorfer, Sandra, Bibi, Sagida, Blackwell, Luke, Brown, Anthony, Brown, Helen, Cavell, Breeze, Clutterbuck, Elizabeth A., de Silva, Thushan, Eyre, David, Lumley, Sheila, Flaxman, Amy, Grist, James, Hackstein, Carl-Philipp, Halkerston, Rachel, Harding, Adam C., Hill, Jennifer, James, Tim, Jay, Cecilia, Johnson, Síle A., Kronsteiner, Barbara, Lie, Yolanda, Linder, Aline, Longet, Stephanie, Marinou, Spyridoula, Matthews, Philippa C., Mellors, Jack, Petropoulos, Christos, Rongkard, Patpong, Sedik, Cynthia, Silva-Reyes, Laura, Smith, Holly, Stockdale, Lisa, Taylor, Stephen, Thomas, Stephen, Tipoe, Timothy, Turtle, Lance, Vieira, Vinicius Adriano, Wrin, Terri, Pollard, Andrew J., Lambe, Teresa, Conlon, Chris P., Jeffery, Katie, Travis, Simon, Goulder, Philip, Frater, John, Mentzer, Alex J., Stafford, Lizzie, Carroll, Miles W., James, William S., Klenerman, Paul, Barnes, Eleanor, Dold, Christina, and Dunachie, Susanna J.

Published
2022
Full Text
View/download PDF

13. Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Author

Serra, Eva Gonçalves, Schwerd, Tobias, Moutsianas, Loukas, Cavounidis, Athena, Fachal, Laura, Pandey, Sumeet, Kammermeier, Jochen, Croft, Nicholas M., Posovszky, Carsten, Rodrigues, Astor, Russell, Richard K., Barakat, Farah, Auth, Marcus K. H., Heuschkel, Robert, Zilbauer, Matthias, Fyderek, Krzysztof, Braegger, Christian, Travis, Simon P., Satsangi, Jack, Parkes, Miles, Thapar, Nikhil, Ferry, Helen, Matte, Julie C., Gilmour, Kimberly C., Wedrychowicz, Andrzej, Sullivan, Peter, Moore, Carmel, Sambrook, Jennifer, Ouwehand, Willem, Roberts, David, Danesh, John, Baeumler, Toni A., Fulga, Tudor A., Carrami, Eli M, Ahmed, Ahmed, Wilson, Rachel, Barrett, Jeffrey C., Elkadri, Abdul, Griffiths, Anne M., Snapper, Scott B., Shah, Neil, Muise, Aleixo M., Wilson, David C., Uhlig, Holm H., and Anderson, Carl A.

Published
2022
Full Text
View/download PDF

14. IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies

Author

Friedrich, Matthias, Pohin, Mathilde, Jackson, Matthew A., Korsunsky, Ilya, Bullers, Samuel J., Rue-Albrecht, Kevin, Christoforidou, Zoe, Sathananthan, Dharshan, Thomas, Tom, Ravindran, Rahul, Tandon, Ruchi, Peres, Raphael Sanches, Sharpe, Hannah, Wei, Kevin, Watts, Gerald F. M., Mann, Elizabeth H., Geremia, Alessandra, Attar, Moustafa, McCuaig, Sarah, Thomas, Lloyd, Collantes, Elena, Uhlig, Holm H., Sansom, Stephen N., Easton, Alistair, Raychaudhuri, Soumya, Travis, Simon P., and Powrie, Fiona M.

Published
2021
Full Text
View/download PDF

15. Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Jairath, Vipul, Feagan, Brian G., Silverberg, Mark S., Danese, Silvio, Gionchetti, Paolo, Löwenberg, Mark, Bressler, Brian, Ferrante, Marc, Hart, Ailsa, Lindner, Dirk, Escher, Armella, Jones, Stephen, Shen, Bo, and Travis, Simon

Abstract

Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements. EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histologic evaluation was performed at baseline, Week (W)14, and W34. Ulcer count, adapted Simple Endoscopic Score for Crohn's Disease in the pouch, and Pouchitis Disease Activity Index histologic component were evaluated. Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 were compared by MH status at W14. Following treatment, mean (standard deviation) number of ulcers in vedolizumab-treated patients reduced from 15.1 (16.4) to 5.0 (4.9) at W14 and 2.7 (3.2) at W34 versus placebo-treated patients with corresponding values of 11.8 (11.3), 13.4 (18.4), and 9.7 (13.8) (vedolizumab vs placebo difference [95% confidence interval]: W14: −8.4 [−14.3, −2.6]; W34: −7.0 [−12.0, −2.0]). More patients receiving vedolizumab versus placebo achieved reduction in ulcerated pouch surface area (W14: 52.4% vs 20.0%; difference, 32.4 percentage points [p.p] [9.7, 51.4]; W34: 52.1% vs 12.9%; difference, 40.2p.p [15.6, 60.3]), absence of ulceration (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [−2.0, 39.5]), Simple Endoscopic Score for Crohn's Disease remission (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [−2.0, 39.5]), and MH (W14: 16.7% vs 2.5%; difference, 14.2p.p [1.9, 26.4]). Patients with MH at W14 had higher rates of Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 than those without. Vedolizumab induced endoscopic improvements in patients with chronic pouchitis, which was associated with improved outcomes at W34, particularly in patients achieving MH at W14. (ClinicalTrials.gov number, NCT02790138.) [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

16. Clinical Performance Status and Technical Factors Affecting Outcomes from Percutaneous Transhepatic Biliary Interventions; A Multicentre, Prospective, Observational Cohort Study

Author

Makris, Gregory C., Macdonald, Andrew C., Allouni, Kader, Corrigall, Hannah, Tapping, Charles R., Hughes, Jane Philips, Anthony, Suzie, Boardman, Phil, Patel, Rafiudin, Wigham, Andrew, Husainy, Mohammad Ali, See, Teik Choon, Cast, James, Olliff, Simon, Travis, Simon, Laasch, Hans-Ulrich, Nice, Colin, and Uberoi, Raman

Published
2021
Full Text
View/download PDF

17. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Author

Ungaro, Ryan C., Yzet, Clara, Bossuyt, Peter, Baert, Filip J., Vanasek, Thomas, D’Haens, Geert R., Joustra, Vincent Wilhelmus, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P., Hébuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollón, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M., Halfvarson, Jonas, Butler, James W., Petersson, Joel, Petralia, Francesca, and Colombel, Jean-Frederic

Published
2020
Full Text
View/download PDF

22. The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.

Author

Paridaens, Kristine, Freddi, Matthew J., and Travis, Simon P. L.

Subjects
ULCERATIVE colitis, MESALAMINE, INFLAMMATORY bowel diseases
Abstract

Mesalazine is an established and recommended first-line treatment for mild-tomoderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor necrosis factor (TNF) agent is not clearly informed from current guidelines. The use of mesalazine is supported by robust clinical evidence supporting its efficacy at inducing remission in patients with moderately active disease. A key advantage of mesalazine is its tolerability profile being similar to that of placebo, which contrasts with that of the corticosteroids and advanced therapies, where there is the potential for significant toxicities. Mesalazine also has cost advantages over anti-TNFs and other advanced therapies. Evidence supports the consideration of all patients with moderately active UC for first-line mesalazine therapy at an optimized dose of ≥4g/d (± 1g/d rectal). Patients responding to treatment within 2 weeks should continue at ≥4g/d for at least 6 months before a dose reduction is considered, since this then alters the pattern of disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial

Author

Vleugels, Jasper L A, Rutter, Matt D, Ragunath, Krish, Rees, Colin J, Ponsioen, Cyriel Y, Lahiff, Conor, Ket, Shara N, Wanders, Linda K, Samuel, Sunil, Butt, Faheem, Kuiper, Teaco, Travis, Simon P L, D'Haens, Geert, Wang, Lai M, van Eeden, Susanne, East, James E, and Dekker, Evelien

Published
2018
Full Text
View/download PDF

26. Development of the Crohn's disease digestive damage score, the Lémann score.

Author

Pariente, Benjamin, Cosnes, Jacques, Danese, Silvio, Sandborn, William J, Lewin, Maïté, Fletcher, Joel G, Chowers, Yehuda, D'Haens, Geert, Feagan, Brian G, Hibi, Toshifumi, Hommes, Daniel W, Irvine, E Jan, Kamm, Michael A, Loftus, Edward V, Louis, Edouard, Michetti, Pierre, Munkholm, Pia, Oresland, Tom, Panés, Julian, Peyrin-Biroulet, Laurent, Reinisch, Walter, Sands, Bruce E, Schoelmerich, Juergen, Schreiber, Stefan, Tilg, Herbert, Travis, Simon, van Assche, Gert, Vecchi, Maurizio, Mary, Jean-Yves, Colombel, Jean-Frédéric, and Lémann, Marc

Subjects
Colon, Humans, Crohn Disease, Disease Progression, Tomography, X-Ray Computed, Magnetic Resonance Imaging, Ultrasonography, Colonoscopy, Severity of Illness Index, Crohn's disease, illness index severity, magnetic resonance imaging, Tomography, X-Ray Computed, Gastroenterology & Hepatology, Clinical Sciences
Abstract

Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article is to outline the methods to develop an instrument that can measure cumulative bowel damage. The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) group. This instrument, called the Crohn's Disease Digestive Damage Score (the Lémann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection. It should not be "diagnostic modality driven": for each lesion and location, a modality appropriate for the anatomic site (for example: computed tomography or magnetic resonance imaging enterography, and colonoscopy) will be used. A total of 24 centers from 15 countries will be involved in a cross-sectional study, which will include up to 240 patients with stratification according to disease location and duration. At least 120 additional patients will be included in the study to validate the score. The Lémann score is expected to be able to portray a patient's disease course on a double-axis graph, with time as the x-axis, bowel damage severity as the y-axis, and the slope of the line connecting data points as a measure of disease progression. This instrument could be used to assess the effect of various medical therapies on the progression of bowel damage.

Published
2011

27. Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Author

Serra, Eva Gonçalves, Schwerd, Tobias, Moutsianas, Loukas, Cavounidis, Athena, Fachal, Laura, Pandey, Sumeet, Kammermeier, Jochen, Croft, Nicholas M., Posovszky, Carsten, Rodrigues, Astor, Russell, Richard K., Barakat, Farah, Auth, Marcus K. H., Heuschkel, Robert, Zilbauer, Matthias, Fyderek, Krzysztof, Braegger, Christian, Travis, Simon P., Satsangi, Jack, Parkes, Miles, Thapar, Nikhil, Ferry, Helen, Matte, Julie C., Gilmour, Kimberly C., Wedrychowicz, Andrzej, Sullivan, Peter, Moore, Carmel, Sambrook, Jennifer, Ouwehand, Willem, Roberts, David, Danesh, John, Baeumler, Toni A., Fulga, Tudor A., Carrami, Eli M., Ahmed, Ahmed, Wilson, Rachel, Barrett, Jeffrey C., Elkadri, Abdul, Griffiths, Anne M., Snapper, Scott B., Shah, Neil, Muise, Aleixo M., Wilson, David C., Uhlig, Holm H., and Anderson, Carl A.

Published
2020
Full Text
View/download PDF

30. 1139 UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Author

Travis, Simon P., primary, Bleakman, Alison Potts, additional, Dubinsky, Marla C., additional, Rubin, David T., additional, Panaccione, Remo, additional, Hibi, Toshifumi, additional, Kayhan, Cem, additional, Gibble, Theresa H., additional, Sapin, Christophe, additional, Flynn, Eoin J., additional, Atkinson, Christian, additional, and Schreiber, Stefan, additional

Published
2023
Full Text
View/download PDF

32. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial

Author

Williams, John G, Alam, M Fasih, Alrubaiy, Laith, Arnott, Ian, Clement, Clare, Cohen, David, Gordon, John N, Hawthorne, A Barney, Hilton, Mike, Hutchings, Hayley A, Jawhari, Aida U, Longo, Mirella, Mansfield, John, Morgan, Jayne M, Rapport, Frances, Seagrove, Anne C, Sebastian, Shaji, Shaw, Ian, Travis, Simon P L, and Watkins, Alan

Published
2016
Full Text
View/download PDF

35. Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

Author

Snowden, John A., Hawkey, Chris, Hind, Daniel, Swaby, Lizzie, Mellor, Katie, Emsley, Richard, Mandefield, Laura, Lee, Ellen, Badoglio, Manuela, Polge, Emmanuelle, Labopin, Myriam, Gribben, John, Pockley, A. Graham, Foulds, Gemma A., Lobo, Alan, Travis, Simon, Parkes, Miles, Satsangi, Jack, Papaioannou, Diana, Lindsay, James O., on Behalf of the Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators, and the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)

Published
2019
Full Text
View/download PDF

36. Value of Engagement in Digital Health Technology Research: Evidence Across 6 Unique Cohort Studies.

Author

Goodday, Sarah M, Karlin, Emma, Brooks, Alexa, Chapman, Carol, Harry, Christiana, Lugo, Nelly, Peabody, Shannon, Rangwala, Shazia, Swanson, Ella, Tempero, Jonell, Yang, Robin, Karlin, Daniel R, Rabinowicz, Ron, Malkin, David, Travis, Simon, Walsh, Alissa, Hirten, Robert P, Sands, Bruce E, Bettegowda, Chetan, and Holdhoff, Matthias

Subjects
FRONTLINE personnel, CENTRAL nervous system tumors, DIGITAL health, MOBILE health, CROHN'S disease
Abstract

Background: Wearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor. Objective: The objective of this paper is to describe how participant engagement techniques and different study designs affect participant adherence, retention, and overall engagement in research involving personal DHTs. Methods: Quantitative and qualitative analysis of engagement factors are reported across 6 unique personal DHT research studies that adopted aspects of a participant-centric design. Study populations included (1) frontline health care workers; (2) a conception, pregnant, and postpartum population; (3) individuals with Crohn disease; (4) individuals with pancreatic cancer; (5) individuals with central nervous system tumors; and (6) families with a Li-Fraumeni syndrome affected member. All included studies involved the use of a study smartphone app that collected both daily and intermittent passive and active tasks, as well as using multiple wearable devices including smartwatches, smart rings, and smart scales. All studies included a variety of participant-centric engagement strategies centered on working with participants as co-designers and regular check-in phone calls to provide support over study participation. Overall retention, probability of staying in the study, and median adherence to study activities are reported. Results: The median proportion of participants retained in the study across the 6 studies was 77.2% (IQR 72.6%-88%). The probability of staying in the study stayed above 80% for all studies during the first month of study participation and stayed above 50% for the entire active study period across all studies. Median adherence to study activities varied by study population. Severely ill cancer populations and postpartum mothers showed the lowest adherence to personal DHT research tasks, largely the result of physical, mental, and situational barriers. Except for the cancer and postpartum populations, median adherences for the Oura smart ring, Garmin, and Apple smartwatches were over 80% and 90%, respectively. Median adherence to the scheduled check-in calls was high across all but one cohort (50%, IQR 20%-75%: low-engagement cohort). Median adherence to study-related activities in this low-engagement cohort was lower than in all other included studies. Conclusions: Participant-centric engagement strategies aid in participant retention and maintain good adherence in some populations. Primary barriers to engagement were participant burden (task fatigue and inconvenience), physical, mental, and situational barriers (unable to complete tasks), and low perceived benefit (lack of understanding of the value of personal DHTs). More population-specific tailoring of personal DHT designs is needed so that these new tools can be perceived as personally valuable to the end user. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs.

Author

Matini, Lawrence, Chapman, Thomas P, Kantschuster, Ramona, Wilson, Jean, Tarafdar, Adib, Hussain, Moheez, Song, Kaiyang, Simadibrata, Daniel M, Seeva, Pavetha, White, Lydia, Slater, Jessica, Kormilitzin, Andrey, Investigators, IBD Cohort, Collins, Gary, Travis, Simon P L, and Walsh, Alissa

Abstract

Background and Aims Digital collection of patient-reported outcome measures [PROMs] is largely unexplored as a basis for follow-up for patients with ulcerative colitis [UC]. Our aim was to develop a model to predict the likelihood of escalation of therapy or intervention at an outpatient appointment that may be used to rationalize follow-up. Methods TrueColours-IBD is a web-based, real-time, remote monitoring software that allows longitudinal collection of ePROMs. Data for prediction modelling were derived from a Development Cohort, guided by the TRIPOD statement. Logistic regression modelling used ten candidate items to predict escalation of therapy or intervention. An Escalation of Therapy or Intervention [ETI] calculator was developed, and applied in a Validation Cohort at the same centre. Results The Development Cohort [ n  = 66] was recruited in 2016 and followed for 6 months [208 appointments]. From ten items, four significant predictors of ETI were identified: SCCAI, IBD Control-8, faecal calprotectin, and platelets. For practicality, a model with only SCCAI and IBD Control-8, both entered remotely by the patient, without the need for faecal calprotectin or blood tests was selected. Between 2018 and 2020, a Validation Cohort of 538 patients [1188 appointments] was examined. A 5% threshold on the ETI calculator correctly identified 343/388 [88%] escalations and 274/484 [57%] non-escalations. Conclusions A calculator based on digital, patient-entered data on symptoms and quality of life can predict whether a patient with UC requires escalation of therapy or intervention at an outpatient appointment. This may be used to streamline outpatient appointments for patients with UC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial

Author

Jairath, Vipul, Kahan, Brennan C, Gray, Alasdair, Doré, Caroline J, Mora, Ana, James, Martin W, Stanley, Adrian J, Everett, Simon M, Bailey, Adam A, Dallal, Helen, Greenaway, John, Le Jeune, Ivan, Darwent, Melanie, Church, Nicholas, Reckless, Ian, Hodge, Renate, Dyer, Claire, Meredith, Sarah, Llewelyn, Charlotte, Palmer, Kelvin R, Logan, Richard F, Travis, Simon P, Walsh, Timothy S, and Murphy, Michael F

Published
2015
Full Text
View/download PDF

48. Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials.

Author

Ahmad, Harris A, East, James E, Panaccione, Remo, Travis, Simon, Canavan, James B, Usiskin, Keith, and Byrne, Michael F

Abstract

Artificial intelligence shows promise for clinical research in inflammatory bowel disease endoscopy. Accurate assessment of endoscopic activity is important in clinical practice and inflammatory bowel disease clinical trials. Emerging artificial intelligence technologies can increase efficiency and accuracy of assessing the baseline endoscopic appearance in patients with inflammatory bowel disease and the impact that therapeutic interventions may have on mucosal healing in both of these contexts. In this review, state-of-the-art endoscopic assessment of mucosal disease activity in inflammatory bowel disease clinical trials is described, covering the potential for artificial intelligence to transform the current paradigm, its limitations, and suggested next steps. Site-based artificial intelligence quality evaluation and inclusion of patients in clinical trials without the need for a central reader is proposed; for following patient progress, a second reading using AI alongside a central reader with expedited reading is proposed. Artificial intelligence will support precision endoscopy in inflammatory bowel disease and is on the threshold of advancing inflammatory bowel disease clinical trial recruitment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems

Author

Byrne, Michael F, primary, Panaccione, Remo, additional, East, James E, additional, Iacucci, Marietta, additional, Parsa, Nasim, additional, Kalapala, Rakesh, additional, Reddy, Duvvur N, additional, Rughwani, Hardik Ramesh, additional, Singh, Aniruddha P, additional, Berry, Sameer K, additional, Monsurate, Ryan, additional, Soudan, Florian, additional, Laage, Greta, additional, Cremonese, Enrico D, additional, St-Denis, Ludovic, additional, Lemaître, Paul, additional, Nikfal, Shima, additional, Asselin, Jerome, additional, Henkel, Milagros L, additional, and Travis, Simon P, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results